# Denis Chem Lab (NSE: DENISCHEM) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/DENISCHEM · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹101 Cr, it ranks 2676th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was 9.5% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹47 Cr (+13.0% year on year) and net profit ₹0 Cr (−43.7%), on a standalone basis. Promoters held 38.98% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹101 Cr |
| ROE | 9.5% (FY25) |
| ROCE | 13.5% (FY25) |
| Debt to equity | 0.01 |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹47 Cr | +13.0% | ₹0 Cr | −43.7% | ₹0.29 |
| Q3 FY26 | ₹46 Cr | +6.3% | ₹3 Cr | +88.6% | ₹2.39 |
| Q2 FY26 | ₹46 Cr | −3.5% | ₹2 Cr | −37.4% | ₹1.60 |
| Q1 FY26 | ₹43 Cr | +4.9% | ₹2 Cr | +19.2% | ₹1.78 |
| Q4 FY25 | ₹41 Cr | +3.8% | ₹1 Cr | −74.0% | ₹0.51 |
| Q3 FY25 | ₹43 Cr | +6.9% | ₹2 Cr | −45.0% | ₹1.27 |
| Q2 FY25 | ₹48 Cr | +5.3% | ₹4 Cr | +39.0% | ₹2.54 |
| Q1 FY25 | ₹41 Cr | −2.9% | ₹2 Cr | −22.4% | ₹1.50 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹173 Cr | ₹8 Cr |
| FY24 | ₹168 Cr | ₹11 Cr |
| FY23 | ₹161 Cr | ₹8 Cr |
| FY22 | ₹137 Cr | ₹6 Cr |
| FY21 | ₹109 Cr | ₹2 Cr |
| FY20 | ₹136 Cr | ₹4 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 38.98%
- Foreign institutions: 0.01%
- Non-institutions: 61.01%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Mercury Labs](https://app.pivotnow.in/stock/MERCURYLAB) | — | ₹102 Cr | — | — |
| [Vaishali Pharma](https://app.pivotnow.in/stock/VAISHALI) | ₹7.49 | ₹101 Cr | 124.8 | — |
| [Concord Drugs](https://app.pivotnow.in/stock/CONCORD) | — | ₹101 Cr | — | — |
| [Fortis Malar](https://app.pivotnow.in/stock/FORTISMLR) | — | ₹97 Cr | — | — |
| [Raaj Medisafe](https://app.pivotnow.in/stock/RAAJMEDI) | — | ₹97 Cr | — | — |
| [KHFM HOSPITALIT](https://app.pivotnow.in/stock/KHFM) | ₹40.90 | ₹95 Cr | — | — |

## Questions and answers

### What is the market cap of Denis Chem Lab?

Denis Chem Lab's market capitalisation is ₹101 Cr (₹101 Cr) at the 22 Oct 2026 close, ranking 2676th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Denis Chem Lab?

Return on equity was 9.5% in FY25 and return on capital employed was 13.5% in FY25 (standalone figures).

### Is Denis Chem Lab a debt-free company?

Denis Chem Lab is close to debt-free: its debt-to-equity ratio was 0.01 in FY25.

### What were Denis Chem Lab's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Denis Chem Lab reported revenue of ₹47 Cr, +13.0% year on year, and net profit of ₹0 Cr, −43.7% year on year.

### What is the shareholding pattern of Denis Chem Lab?

As of 30 Jun 2026: promoters 38.98%, foreign institutions 0.01%, non-institutions 61.01%.

### Who are Denis Chem Lab's competitors?

The listed Pharma & Healthcare companies closest to Denis Chem Lab by market cap are Mercury Labs, Vaishali Pharma, Concord Drugs, Fortis Malar, Raaj Medisafe and KHFM HOSPITALIT.

### Is Denis Chem Lab a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Denis Chem Lab's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on DENISCHEM against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.